TP53 and B-cell chronic lymphocytic leukemia: Consistent with these clinical observations, in vitro experiments suggest that although venetoclax is active against p53 perturbed CLL [137], these lesions facilitate survival and the evolution of resistance with prolonged sublethal exposure to BCL2 inhibition [138].